Clinical management of patients with non-small cell lung cancer, brain metastases, and actionable genomic alterations: a systematic literature review
M Khasraw, P Yalamanchili, A Santhanagopal… - Advances in …, 2024 - Springer
Introduction Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with
metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis …
metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis …
[HTML][HTML] Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer
SA Laurie, S Banerji, N Blais, S Brule… - Current …, 2019 - ncbi.nlm.nih.gov
Background Little evidence has been generated for how best to manage patients with non-
small-cell lung cancer (nsclc) presenting with rarer clinical scenarios, including …
small-cell lung cancer (nsclc) presenting with rarer clinical scenarios, including …
Tyrosine Kinase Inhibitors in Cancers: treatment optimization–Part I
D Combarel, L Dousset, S Bouchet, F Ferrer… - Critical Reviews in …, 2024 - Elsevier
A multitude of TKI has been developed and approved targeting various oncogenetic
alterations. While these have provided improvements in efficacy compared with …
alterations. While these have provided improvements in efficacy compared with …
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung …
PL Su, YL Wu, WY Chang, CL Ho… - Therapeutic …, 2018 - journals.sagepub.com
Introduction: Brain metastases (BM) are common in advanced non-small cell lung cancer
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …
(NSCLC), and the prognosis is poor with few therapeutic options. This study evaluated the …
Inhomogeneous tumor dose distribution provides better local control than homogeneous distribution in stereotactic radiotherapy for brain metastases
F Lucia, S Key, G Dissaux, G Goasduff, AS Lucia… - Radiotherapy and …, 2019 - Elsevier
Introduction The aim of this study was to analyze the impact of inhomogeneous versus
homogeneous dose distribution on local control (LC) and radionecrosis (RN) in patients …
homogeneous dose distribution on local control (LC) and radionecrosis (RN) in patients …
Therapeutic schedule evaluation for brain-metastasized non-small cell lung cancer with a probabilistic linguistic ELECTRE II method
With the rapid development of modern medicine, therapeutic schedules of brain-
metastasized non-small cell lung cancer (NSCLC) are expanding. To assist a patient who …
metastasized non-small cell lung cancer (NSCLC) are expanding. To assist a patient who …
Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
Y Saida, S Watanabe, T Abe, S Shoji, K Nozaki… - Thoracic …, 2019 - Wiley Online Library
Background Although the clinical efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR‐TKIs) in EGFR‐mutant non‐small cell lung cancer (NSCLC) patients has …
inhibitors (EGFR‐TKIs) in EGFR‐mutant non‐small cell lung cancer (NSCLC) patients has …
Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis
Background Cancer metastasis and drug resistance have traditionally been studied
separately, though these two lethal pathological phenomena almost always occur …
separately, though these two lethal pathological phenomena almost always occur …
Genomics of breast cancer brain metastases: a meta-analysis and therapeutic implications
Simple Summary Breast cancer brain metastases are a challenging daily practice, and the
biological link between gene mutations and metastatic spread to the brain remains to be …
biological link between gene mutations and metastatic spread to the brain remains to be …
The role of stereotactic radiosurgery in the management of brain metastases from a health-economic perspective: a systematic review
BACKGROUND Stereotactic radiosurgery (SRS) is an effective option in the management of
brain metastases, offering improved overall survival to whole-brain radiation therapy …
brain metastases, offering improved overall survival to whole-brain radiation therapy …